Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 110 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson Disease
Interventions
SAGE-217, Levodopa, Antiparkinsonian Agent(s)
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Panorama City, California • Jacksonville, Florida • Miami, Florida + 7 more
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Parkinson's Disease
Interventions
Placebo, IPX066 95 mg LD, IPX066 145 mg LD, IPX066 195 mg LD, IPX066 245 mg LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Garden Grove, California + 22 more
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Completed Not applicable Interventional Results available

PharmacoMRI of Parkinson Disease

NCT01528592
Conditions
Parkinson's Disease
Interventions
Carbidopa-Levodopa
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Parkinson's Disease
Interventions
Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Peoria, Arizona • Bingham Farms, Michigan
Conditions
Parkinson's Disease
Interventions
ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, Placebo for Oral IR-LD/CD
Combination Product · Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Conditions
Advanced Parkinson's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Boca Raton, Florida • Gainesville, Florida + 16 more
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
carbidopa-levodopa, Placebo Oral Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Parkinson Disease
Interventions
NE3107, placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
16
States / cities
Englewood, Colorado • Boca Raton, Florida • Hallandale, Florida + 10 more
Conditions
Parkinson's Disease
Interventions
Levodopa
Drug
Lead sponsor
Kevin J. Black, MD
Other
Eligibility
40 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years to 99 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 25 more
Conditions
Parkinson's Disease (PD)
Interventions
Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Port Charlotte, Florida • Round Rock, Texas
Conditions
Parkinson's Disease
Interventions
levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Stroke
Interventions
Placebo, Levodopa / Carbidopa, Armeo
Drug · Device
Lead sponsor
Ross D. Zafonte, MD
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1, Placebo 2
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Ann Arbor, Michigan
Conditions
Spinal Cord Injuries
Interventions
CPH + hand training, CD-LD + hand training, ATX + hand training, Placebo + hand training
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Completed Phase 4 Interventional Results available

DTA (Dopaminergic Therapy for Anhedonia) Study

NCT04723147
Conditions
Depression, Anhedonia
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Results available

Carbidopa-levodopa in Neovascular AMD

NCT03022318
Conditions
Age-related Macular Degeneration
Interventions
carbidopa-levodopa 25-100 mg tablets
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
Fresno, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Completed Phase 2Phase 3 Interventional Results available

Augmenting Language Therapy for Aphasia: Levodopa

NCT01429077
Conditions
Nonfluent Aphasia, Stroke
Interventions
levodopa/carbidopa, Placebo comparator
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Advanced Parkinson's Disease
Interventions
Sinemet, IPX203
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Boca Raton, Florida • Naples, Florida + 7 more
Conditions
Parkinson's Disease
Interventions
ND0612
Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 23 more
Conditions
Idiopathic Parkinson Disease
Interventions
XADAGO (safinamide)
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Homewood, Alabama • Bakersfield, California • Laguna Hills, California + 27 more